Abstract
AHR-13268D (4-[3-[4-[Bis(4-flurophenyl)hydroxymethyl]-1-piperidinyl]propoxy]benzoic acid, sodium salt) is a potent, long-acting water soluble, antiallergic and antihistaminic agent. AHR-13268D protects sensitive guinea pigs from collapse induced by aerosolized antigen; 1, 5, and 24 h ED50s in the test were 0.27, 0.25, 0.93 mg/kg, PO, respectively. AHR-13268D was also active when given as an aerosol, the 1 h ED50=0.29%. In the rat passivefoot anaphylaxis test, AHR-13268D was slightly more active (1.55 times) than AHR-5333B when given orally 1 h prior to challenge and equipotent to cromolyn when given intravenously immediately prior to challenge. AHR-13268D displayed potent, long-acting antihistaminic activity in naive guinea pigs; the 1, 5, and 24 h oral ED50s being in the range of 0.3 mg/kg. AHR-13268D (10 to 20 mg/kg, PO) attenuated the skin responses to ascaris antigen in sensitive dogs and did not alter the EEG pattern or sleep/wake patterns of cats at doses in vast excess of its antihistaminic activity.In vitro, AHR-13268D was a potent inhibitor of histamine release from rat peritoneal mast cells (IC50=0.51 nM) and was as potent as the reference 5-LO inhibitor phenidone in inhibiting antigen-induced contractions of guinea pig ileum in the presence of pyrilamine, atropine, and imidazole (IC50∼300 μM). AHR-13268B was bioavailable (∼88%) from capsules or from oral solutions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
J. Vanni and M. Foxwell,Effects of AHR-5333, a new potential antiallergy compound, in in vivo models of immediate hypersensitivity. Int. Archs. Allergy Appl. Immun.85, 428–433 (1988).
D. Walsh and J. Yanni,AHR-5333B. Drugs of the future13, 605–609 (1989).
D. Walsh, S. Franzyshen and J. Yanni,Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3- (aryloxy)-propyl]piperidines and structurally related compounds. J. Med. Chem.32, 105–118 (1989).
J. Yanni, R. Halliwell and C. Tracy,Effects of AHR-5333 on flea antigen extract-induced skin reactions in flea-allergic dogs. J. Vet. Pharmacol. Therap.11, 221–225 (1988).
G. Graff, L. Anderson and L. Jefferson Jr.,AHR-5333, a new antiallergy compound. III. In vitro inhibition of 5-lipoxygenase and glutathione-S-transferse activity. J. Allergy Clin. Imm.81, 235 (1988).
M. Foxwell, L. Whitman and J. Yanni,AHR-5333, a new antiallergy compound. II. Inhibition of mediator release/responses in vitro. J. Allergy Clin. Imm.81, 250 (1988).
R. Martel and J. Klicius,Reagin-mediated hypersensitivity reaction in the rat hindpaw and its inhibition by antianaphylactic drugs. Int. Archs. Allergy Appl. Immun.55, 205–209 (1977).
J. Yanni, W. Smith, E. Callaham, M. Foxwell and R. Alphin,A method for measuring changes in tracheal mucus gel layer thickness as an indication of an immediate hypersensitivity response. Int. Archs. Allergy Appl. Immun.74, 351–355 (1984).
P. Anderson and H. Bergstrand,Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs: effect of long-term treatment with sodium cromoglycate and aminophylline. Br. J. Pharmacol.74, 601–609 (1981).
C. Faingold and C. Berry,Effects of antihistamine agents upon the electrographic activity of the cat brain: a power spectral density study. Neuropharmacology11, 491–498 (1972).
R. Ruckart and D. Johnson,Effects of antihistaminic agents on sleep patterns in cats: a new method for detecting sedative potential. Pharmacologist.25 (Abstract), 180 (1983).
D. Johnson, W. Funderburk and J. Ward,Comparative effects of ten anorectic drugs on sleep-wakefulness patterns in cats. Eur. J. Phrmacol.15, 176–179 (1971).
C. Dunnett,A multiple comparison procedure comparing several treatments with a control. J. Am. Stat. Assoc.50, 1096–1121 (1955).
M. Rose, W. Hageman and F. Persico,The sensitive lung strips as a model to detect agents that inhibit the formation/activity of lipoxygenase products. Pharmacologist25, 123 (1983).
A. Nicholson and B. Stone,Antihistamine impaired performance and the tendency to sleep. Eur. J. Pharmacol.30, 27–32 (1986).
T. Roehrs, E. Tietz, F. Zorick and T. Roth,Daytime sleepiness and antihistamines. Sleep7, 137–141 (1984).
A. Nicholson,A new antihistamine free of sedative side effects. TIPS8, 247–249 (1987).
N. Welch and J. Martin,Absence of an effect of terfenadine on guinea pig brain H 2-receptor in vivo determined by receptor binding techniques. Arzneim.-Forsch./Drug. Res.32 1167–1170 (1982).
A. Barnett, L. Iorio, W. Kreutner, S. Tozzi, H. Ahn and A. Gulbenkian,Evaluation of the CNS properties of SCH 29851, a potential nonsedating antihistamine. Agents and Actions14, 590–597 (1984).
A. Ahn and A. Barnett,Selective displacement of [ 3H]mepyramine from peripheral vs. central nervous system receptor by loratadine. Eur. J. Pharmacol.127, 153–155 (1986).
J. Van Wauwe, F. Awouters, C. Neimegeers, F. Janssens, J. Van Neuten and P. Janssen,In vivo pharmacology of astemizole, a new type of H 2-antihistaminic compound. Arch. Int. Pharmacodyn.251, 39–51 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nolan, J.C., Foxwell, M.H., Whitman, L.L. et al. Thein vivo andin vitro activity of AHR-13268D, a new antiallergic/antihistaminic agent. Agents and Actions 31, 210–218 (1990). https://doi.org/10.1007/BF01997610
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01997610